BSE filing, NSE: CONCORD. Summary written from the filing by ALFA Finder's alert engine.
Concord Drugs Ltd: key numbers
- Share price
- ₹63.55
- Market cap
- ₹83.73 Cr
- Revenue (annual)
- ₹78.74 Cr
- Net profit (annual)
- ₹1.06 Cr
- P/E (TTM)
- 40.8×Sector 45.9×
- Promoter holding
- 45.08%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Drugs Ltd
All →Concord Drugs Other Announcement
Concord Drugs Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per SEBI regulations.
Concord Drugs Annual General Meeting
Concord Drugs Limited held its 31st Annual General Meeting on September 30, 2026. The meeting covered adoption of financial statements, director appointments, and auditor re-appointment.
Concord Drugs Other Announcement
Concord Drugs Limited is notifying shareholders about the annual report web-link as per Regulation 36(1)(b). Shareholders are urged to update their email addresses.
Concord Drugs Annual Report
Concord Drugs Limited submitted its 31st Annual Report for FY 2025-26 and notice of the 31st Annual General Meeting scheduled for 30th September 2026.
Concord Drugs Annual General Meeting
Concord Drugs approved the notice for its 31st AGM on September 30, 2026. The board also finalized director re-appointments and set book closure dates.
Concord Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 1000.0% YoY
Concord Drugs Ltd reported revenue from operations of ₹20.9 Cr (+53.7% YoY) and net profit of ₹1.1 Cr (+1000.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · +1000.0% YoY
Other debt & borrowing announcements
All →Birla Corporation Debt & Borrowing: ₹250 Cr
Birla Corporation board approved enabling resolution for issuing up to Rs.250 Crore of listed secured/unsecured NCDs on private placement. Funds will be raised through debt within overall borrowing limits.
- Value
- ₹250.0 Cr
- Execution
- As may be decided by the Authorised Person (tenure not fixed)
Poonawalla Fincorp Debt & Borrowing: ₹0.72 Cr
Poonawalla Fincorp paid interest of about Rs 0.72 Crore on its NCDs (ISIN INE511C07961) on 31 October 2026, on time. This is a Regulation 57 certificate confirming a routine debt servicing payment.
- Value
- ₹0.72 Cr
Poonawalla Fincorp Debt & Borrowing: ₹73.95 Cr
Poonawalla Fincorp paid timely interest of Rs 73.95 Crore on its NCDs due October 31, 2026. Payment covers the annual coupon on the Rs 1,000 Crore issue.
- Value
- ₹73.95 Cr
Hinduja Leyland Finance Debt & Borrowing
Hinduja Leyland Finance reported that no put option exercise requests were received for NCD ISIN INE146O07508 by the September 30, 2026 deadline. It asked BSE not to suspend trading and to revoke the October 30 record date.
Muthoot Finance Debt & Borrowing
Muthoot Finance submitted its September 30, 2026 security cover statement for secured NCDs. The auditors certify the cover is adequate under the trust deeds.
IFCI Debt & Borrowing: ₹102.5 Cr
IFCI Ltd fully redeemed its 10.75% subordinated NCD (ISIN INE039A09NW0) at maturity on 31 October 2026. The redemption amount was ₹102.49 Crore, leaving no outstanding balance.
- Value
- ₹102.5 Cr